Camilo Jiménez
YOU?
Author Swipe
View article: MON-488 Metastatic Paraganglioma With a Supraglottic Laryngeal Primary in a Patient With an SDHA Pathogenic Variant
MON-488 Metastatic Paraganglioma With a Supraglottic Laryngeal Primary in a Patient With an SDHA Pathogenic Variant Open
Disclosure: T.D. Cubb: None. C.M. Skefos: None. R.P. Goepfert: None. M.D. Williams: None. C. Jimenez: None. Introduction: The succinate dehydrogenase (SDH) complex is a tumor suppressor, and pathogenic variants (PV) in its four subunits ar…
View article: SAT-474 Gemcitabine Oxaliplatin Combination in Patients with Advanced Adrenocortical Carcinoma
SAT-474 Gemcitabine Oxaliplatin Combination in Patients with Advanced Adrenocortical Carcinoma Open
Disclosure: L. Chen: None. V. Balderrama Brondani: None. L.P. Marcal: None. C. Jimenez: None. J. Varghese: None. A.Y. Shah: None. M.A. Habra: None. M.T. Campbell: None. Background: Adrenocortical cancer (ACC) is a rare and aggressive malig…
View article: OR32-06 Circulating Tumor DNA Analysis in Adrenocortical Carcinoma - A First Retrospective Cohort Study
OR32-06 Circulating Tumor DNA Analysis in Adrenocortical Carcinoma - A First Retrospective Cohort Study Open
Disclosure: V. Balderrama Brondani: None. L.P. Marcal: None. M.J. Moussa: None. A.Y. Shah: None. P.H. Graham: None. J. Varghese: None. C. Jimenez: None. M.T. Campbell: None. M.A. Habra: None. Background: Circulating tumor DNA (ctDNA) analy…
View article: SUN-264 Head and Neck Paragangliomas in Two Patients With Multiple Endocrine Neoplasia 2B
SUN-264 Head and Neck Paragangliomas in Two Patients With Multiple Endocrine Neoplasia 2B Open
Disclosure: J.M. Kaplan: None. C. Jimenez: None. S. Hosseini: None. S.G. Waguespack: None. Background: Multiple endocrine neoplasia type 2B (MEN2B) is a hereditary tumor syndrome primarily caused by the germline p.M918T RET pathogenic vari…
View article: Disease-specific mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis
Disease-specific mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis Open
Graphical Abstract Abstract Objective Characterize disease-specific mortality rates in patients with acromegaly on pegvisomant and identify pertinent risk factors, including on-therapy insulin-like growth factor I (IGF-I) levels. Design Re…
View article: Patient-derived organoids reveal hypoxia-driven plasticity and therapeutic vulnerabilities in pheochromocytomas and paragangliomas
Patient-derived organoids reveal hypoxia-driven plasticity and therapeutic vulnerabilities in pheochromocytomas and paragangliomas Open
Pheochromocytomas and paragangliomas (PPGLs) are rare chromaffin cell-derived neuroendocrine tumors of sympathetic (catecholamine-producing) or parasympathetic (nonsecretory) origin, frequently driven by dysregulation of hypoxia-inducible …
View article: 7959 Combination Therapy Of Multi-Targeted Tyrosine Kinase Inhibitors And Immune Checkpoint Inhibitors In Advanced Adrenocortical Carcinoma
7959 Combination Therapy Of Multi-Targeted Tyrosine Kinase Inhibitors And Immune Checkpoint Inhibitors In Advanced Adrenocortical Carcinoma Open
Disclosure: F. Yaylaci Mert: None. V. Balderrama Brondani: None. L.P. Marcal: None. M. Campbell: None. C. Jimenez: None. J. Varghese: None. A. Shah: None. M.A. Habra: None. Background: Adrenocortical carcinoma (ACC) is a rare cancer with l…
View article: Author Correction: International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents
Author Correction: International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents Open
View article: International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents
International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents Open
View article: Management of metastatic pheochromocytomas and paragangliomas: when and what
Management of metastatic pheochromocytomas and paragangliomas: when and what Open
Recently, the treatment landscape for metastatic pheochromocytomas and paragangliomas (MPPGL) has seen both progress and setbacks. We provide an up-to-date review of the multimodality management of MPPGL and discuss novel opportunities and…
View article: Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma
Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma Open
Metastatic pheochromocytomas and paragangliomas (PPGLs) are frequently associated with skeletal complications. Primary objective: to describe the frequency of adverse skeletal related events (SREs) in PPGL patients with bone metastases (BM…
View article: Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis
Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis Open
Background Venous thromboembolism (VTE) is a leading cause of death in patients with cancer. Limited data exist about VTE in patients with adrenocortical carcinoma (ACC). The primary objective of this study was to identify the prevalence o…
View article: Perspective review: lessons from successful clinical trials and real-world studies of systemic therapy for metastatic pheochromocytomas and paragangliomas
Perspective review: lessons from successful clinical trials and real-world studies of systemic therapy for metastatic pheochromocytomas and paragangliomas Open
Pheochromocytomas and paragangliomas (PPGLs) are orphan tumors with the potential to spread to distant organs such as the lymph nodes, the skeleton, the lungs, and the liver. These metastatic tumors exhibit high rates of morbidity and mort…
View article: 630 EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1–19/SPENCER study
630 EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1–19/SPENCER study Open
Background EOADR1–19/SPENCER study is a phase 1/2 trial of EO2401, evaluating the combination of EO2401 with nivolumab, for the treatment of patients with locally advanced or metastatic adrenocortical carcinoma (ACC) or malignant pheochrom…
View article: 724O EO2401 (E) peptide immunotherapy + nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP): EOADR1-19/SPENCER
724O EO2401 (E) peptide immunotherapy + nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP): EOADR1-19/SPENCER Open
View article: FRI191 Changes In The Incidence And Geographical Distribution Of Adrenocortical Carcinoma: A Retrospective Analysis Of A State Cancer Registry
FRI191 Changes In The Incidence And Geographical Distribution Of Adrenocortical Carcinoma: A Retrospective Analysis Of A State Cancer Registry Open
Disclosure: V.B. Brondani: None. A.M. Griffin: None. T.J. Owen: None. K.W. Merriman: None. J.M. Varghese: None. C. Jimenez: None. S.G. Waguespack: None. P.H. Graham: None. M.T. Campbell: None. M.M. Hassan: None. M.A. Habra: None. Backgroun…
View article: Supplementary Tables S1-S12 from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma
Supplementary Tables S1-S12 from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma Open
Basic patients characteristics of the cohort used for serum HGF measurements ; Patients characteristics of second TMA ; Genes with significantly (P {less than or equal to} 0.05, absolute value of log ratio > 0.1) changed expression in tumo…
View article: Data from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma
Data from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma Open
Adrenocortical carcinoma is a rare malignancy with poor prognosis and limited response to chemotherapy. Hepatocyte growth factor (HGF) and its receptor cMET augment cancer growth and resistance to chemotherapy, but their role in adrenocort…
View article: Supplementary Table Legend from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma
Supplementary Table Legend from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma Open
Supplementary Table Legend from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma
View article: Supplementary Table Legend from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma
Supplementary Table Legend from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma Open
Supplementary Table Legend from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma
View article: Data from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma
Data from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma Open
Adrenocortical carcinoma is a rare malignancy with poor prognosis and limited response to chemotherapy. Hepatocyte growth factor (HGF) and its receptor cMET augment cancer growth and resistance to chemotherapy, but their role in adrenocort…
View article: Supplementary Figures S1-S6 from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma
Supplementary Figures S1-S6 from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma Open
High MET expression in ACC patients (S1); High MET mRNA expression levels in ACC (S2); cMET signaling is activated in ACC (S3); Increased HGF/cMET signaling is associated with enhanced proliferation and reduced apoptosis in tumors from ACC…
View article: Supplementary Tables S1-S12 from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma
Supplementary Tables S1-S12 from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma Open
Basic patients characteristics of the cohort used for serum HGF measurements ; Patients characteristics of second TMA ; Genes with significantly (P {less than or equal to} 0.05, absolute value of log ratio > 0.1) changed expression in tumo…
View article: Supplementary Figures S1-S6 from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma
Supplementary Figures S1-S6 from Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma Open
High MET expression in ACC patients (S1); High MET mRNA expression levels in ACC (S2); cMET signaling is activated in ACC (S3); Increased HGF/cMET signaling is associated with enhanced proliferation and reduced apoptosis in tumors from ACC…
View article: A Phase II Clinical Trial of Cabozantinib Monotherapy for Advanced Adrenocortical Carcinoma
A Phase II Clinical Trial of Cabozantinib Monotherapy for Advanced Adrenocortical Carcinoma Open
View article: Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma
Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma Open
The objective of this study is to present the complete biomarker response dataset from a pivotal trial evaluating the efficacy and safety of high-specific-activity I-131 meta-iodobenzylguanidine in patients with advanced pheochromocytoma o…
View article: Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia
Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia Open
Tumors driven by deficiency of the VHL gene product, which is involved in degradation of the hypoxia-inducible factor subunit 2 alpha (HIF2α), are natural candidates for targeted inhibition of this pathway. Belzutifan, a highly specific an…
View article: American Association of Endocrine Surgeons Guidelines for Adrenalectomy
American Association of Endocrine Surgeons Guidelines for Adrenalectomy Open
Importance Adrenalectomy is the definitive treatment for multiple adrenal abnormalities. Advances in technology and genomics and an improved understanding of adrenal pathophysiology have altered operative techniques and indications. Object…
View article: Management of adrenocorticotropic hormone-secreting neuroendocrine tumors and the role of bilateral adrenalectomy in ectopic Cushing syndrome
Management of adrenocorticotropic hormone-secreting neuroendocrine tumors and the role of bilateral adrenalectomy in ectopic Cushing syndrome Open
View article: Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience
Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience Open
Context Reporting temporal trends in adrenocortical carcinoma (ACC) helps guide management strategies. Objective This work aimed to report the trends in disease burden and clinical outcomes over time that cannot be adequately captured from…